

## REMARKS

Claims 1, 5, 7 to 14, and 16 to 19 are pending. Claims 1, 5, and 7 to 14 have been amended. Claims 16 to 19 are new. Claims 2 to 4, and 6 have been cancelled herein. Claim 15 was previously cancelled.

A new sequence listing in compliance with 37 CFR §§1.821-1.825 is enclosed along with an identical CRF version.

A substitute specification is enclosed that overcomes the objections set forth in items 4 and 5 of the Office Action.

IOR C5 hybridoma was accepted on June 11, 1997 as a patent deposit with the European Collection of Cell Cultures in accordance with the Budapest Treaty of 1977. Access to the deposit will be available during pendency of the patent application making reference to the deposit to one determined by the Commissioner to be entitled thereto under 37 CFR 1.14 and 35 U.S.C. 122. All restrictions imposed by the depositor on the availability to the public of the deposited material will be irrevocably removed upon the granting of the patent. A copy of the deposit certificate is enclosed herewith.

The instructing Attorneys for this application have reviewed the Office Action and cited references, and provide the following comments.

The examiner rejects claims 1-14 as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicants regards as the invention. In order to overcome this rejection, "recombinant antibody" and "single chain Fv fragment" are separated in different independent claims.

On the other hand the examiner rejects claims 1-14 arguing that the specification does not enable any person skilled in the art to which pertains, or with which it is most nearly connected, to use the invention because the specification does not provide evidence that the claimed biological material are (1) known and readily available to the public; (2) reproducible from the written description. Although the examiner recognizes that the applicant refers to the deposit of the murine monoclonal antibody IOR C5 on page 4 of the specification, he considers that it is an insufficient assurance that the required deposit has been made and all the conditions of 37CFR 1.801-1-809 met.

In order to overcome this rejection we are sending attached a copy of the Deposit Certificate received from the Depositary Authority corresponding to the murine hybridoma, producer of the monoclonal antibody IOR C5, from which the recombinant variants and fragments claimed are obtained. Said deposit, according to the Budapest Treaty, was accepted by this Authority, and all restrictions upon public access to the deposited material will be irrevocably removed upon the grant of a patent on this application. We hope that with these documents the examiner considers that the mentioned requirements are fulfilled.

Additionally the examiner rejects claims 1-14 considering that the specification does not reasonably provide enablement for an antibody or single chain fragment that does not bind the IOR C2 antigen. Due to the intention of the applicant is precisely to protect any recombinant antibody or single chain Fv fragment derived from the monoclonal antibody IOR C5, trying to preserve the specificity for the antigen IOR C2 and reducing immunogenicity, we have introduced the referred limitation in the new set the claims proposed, with which we hope to overcome said rejection.

Finally the examiner considers that the present claims are not novel and obvious from the prior art consisting in the documents of Iznaga Escobar et al, Bird et al, and Adair et al. In order to overcome the novelty rejection, in the set of claims sent we have fused the content of the present claims 1 to 4, with which the applicant distinguishes the recombinant antibodies and fragments derived from the murine monoclonal antibody IOR C5 of the present invention with respect to the putative antibodies of the document of Iznaga Escobar.

In connection to the examiner's criteria about the obviousness of the present claims at the light of the prior art, the applicant respectfully disagrees with this examiner's criteria.

As mentioned previously, the document of Iznaga Escobar discloses putative humanized antibodies, which eventually could be obtained from murine antibody IOR C5 with the properties claimed in such patent application; however this document does

not provide any enabling disclosure to get humanized antibodies as those specifically claimed in the present patent application. In this reference neither any data in respect of the supposed sequences of said humanized antibodies nor data of deposited material in connection to these antibodies are disclosed. The Examiner should understand that it is not the same to try to achieve a result with reasonable expectation of success, that getting said results successfully.

The present invention is referred to particular humanized monoclonal antibodies. None of the previous publications have provided antibody variable regions humanized sequences which would allow any person skill in the art to obtain, in practice, such recombinant antibodies, by means of genetic engineering techniques and to improve said molecules in order they maintain the affinity for the original antigen but, at the same time, are less immunogenic and better tolerated when they are used as therapeutic or diagnostic agent in humans.

In relation to the references cited, although the previous art discloses the murine monoclonal antibody IOR C5, as well as methods of humanization of murine monoclonal antibodies in general, the humanization of each antibody requires of innovative steps (non obvious solutions) in order to achieve successfully this goal, it means: selection of human framework residues, mutations in said human framework residues to maintain the binding affinity and, at the same time reducing immunogenicity. Thus, many different humanized antibodies could be eventually obtained from a murine antibody, each one being a synthetic product obtained by genetic engineering.

The applicant has found that for VH sequences, residues 10 (ASP) and 17 (SER) should be replaced by GLY and THR respectively, and furthermore that second mutations were necessary at positions 43 and 44, wherein LYS and GLY substituted ASN and LYS, respectively. On the other hand for VK sequences, mutations must be done in positions 15, 45 and 63, substituting ILE, LY and THR by LEU, ARG and SER respectively.


All of the above mentioned conclusions are based on experimental evidences shown in the present application and never described before. Thus, the only document that discloses how to obtain, from murine monoclonal antibody IOR C5, useful variants of recombinant antibodies or fragments derived thereof is the present invention.

For all above argued we respectfully disagree with the Examiner's criterion about the lack of inventive step of the claims 1-14.

Applicants respectfully request favorable consideration and that the claims of this application be passed to allowance.

Date: \_\_\_\_\_

Respectfully submitted,

  
\_\_\_\_\_  
Thomas Blankinship  
Reg. No. 39,909



## **ANTIBODIES AND FV FRAGMENT RECOGNIZING ANTIGEN IOR C2.**

MARKED  
VERSION

### **FIELD OF THE INVENTION**

This invention is related to the field of the biotechnology and in particular with new recombinant antibodies obtained using genetic engineering technology, specifically with a chimeric antibody, a humanized antibody and a single chain Fv fragment obtained from murine ior C5 antibody, which recognize epitopes expressed in ior C2 antigen which has been characterised as glycoprotein complex which is expressed in normal and malignant colorectal cells.

### **BACKGROUND OF THE INVENTION**

They have been tested different forms of colorectal carcinoma treatment, however up to day the surgery it has been the only curative way. The surgery has allowed reaching higher percents of survival, when the detection of the tumour is in an early stage, but unfortunately the most cases are diagnosticated when the tumour has metastized.

In this moment, the strategy to increase survival includes the diagnosis, the therapeutic and epidemiology, in stages wherein it has not been produced the dissemination of the disease to external layers of the organs and the tumour is still surgically curable. In the way, the knowledge of epidemiological factors as well as the development of new therapeutically methods will help to increase the survival.

The use of monoclonal antibodies (Mabs) or their fragments, labelled with radioactive isotopes for the detection of cancer through immunogammagraphic

methods, has been used in the last years. The Mabs have shown potential to be used as carriers of radioisotopes and to be targeted to the associated tumour antigens.

Some of the radiolabelled antibodies have been used to detect tumours associated with carcinoembryonic antigens (CEA). The antibodies against CEA, labelled with I-131 or I-125 are used to detect tumours producing CEA or associated with this marker (Patents US No. 3 663 684, US No. 3 867 363 y US No. 3 927 193). Also, Mabs can be labelled with Tc-99m to get molecules for "in vivo" diagnosis.

The development of the hybridoma antibody technique by Köhler and Milstein revolutionised the discipline of immunochemistry and provided a new family of reagents with potential applications in the research and clinical diagnosis of diseases (Köhler G; Milstein C. (1975) Nature 256, 495-497). These antibodies have not shown strong therapeutic efficacy, while it has become routine to produce mouse monoclonal antibodies (mAbs) for use in basic research and clinical diagnosis, it has been difficult to use these for "in vivo" immunotherapy, because they have reduced half life in humans, poor recognition of mouse antibodies effector domains by the human immune system and also because foreign immunoglobulins can elicit an antiglobulin response (HAMA response) that may interfere with therapy.

The development of the genetic engineering has revolutionised the ability to genetically manipulate antibody genes and then to produce mAbs having decreased or eliminated antigenicity and enhanced desired effector functions, when these antibodies are used in the treatment or diagnosis of some pathologies. These

manipulations have provided an alternative where a murine mAb can be converted to a predominantly human form with the same antigen binding properties (Morrison S. L; et al 1984, P.N.A.S. USA, 81,6851-6855).

Recently they have been developed some methods in order to humanise murine or rat antibodies and decrease xenogenic response against foreign proteins when they are used in humans.

One of the first intents to reduce antigenicity, has been by producing "chimeric" antibodies. In these molecules, the variable domains were inserted into human frameworks, in this way not only it can be reached the decrease of the immunogenicity but also the improvement of effector functions, because they are humans and therefore recognised by the immune system (Morrison S. L et al (1984) P.N.A.S, USA 81, 6851-6855). These chimeric molecules retain the recognition of the original antigen and its constant region is not immunogenic, although the immunogenicity against murine variable region is retained.

Other authors have attempted to build rodent antigens binding sites directly into human antibodies by transplanting only the antigen binding site, rather than the entire variable domain, from a murine antibody (Jones P.T et al (1986) Nature 321, 522- 524, Verhoeyen M et al (1988) Science 239, 1534-1536). They have been developed some applications of this method by Rietchmann (Rietchmann L. et al (1988) Nature 332, 323-327; Quee C. et al (1989) P.N.A.S USA 86,10029-10033), however other authors have worked with reshaped antibodies, which included some



murine residues in human FRs in order to recover the affinity for the original antigen (Tempest, P.R (1991) Biotechnology 9, 266-272).

Mateo et al. (US Patent Number US 5712120) described a procedure to reduce immunogenicity of the murine antibodies. In this procedure, the modifications are restricted to the variable domains and specifically to the murine frameworks of the chimeric antibodies. Even more, these modifications are only carried out in the FRs regions with amphipatic helix structure, therefore are potential epitopes recognised by T cells. The method proposes to substitute the murine residues inside the amphipatic regions, by the amino acids in the same positions in the human immunoglobulines, of course the amino acids involved in the tridimensional structure of the binding site, it means Vernier's zone, canonical structures of the CDRs and the amino acid of the inter-phase between light and heavy chain are excluded.

The antibody modified by the method described by Mateo et al, retains the capacity of the recognition and binding to the antigen, that recognised the original antibody and it results less immunogenic because of this it is got an increase of the therapeutic efficacy. Through this procedure only few mutations are necessary to obtain modified antibodies that shown reduced immunogenicity compared with chimeric antibodies.

The IOR C5 murine monoclonal antibody (patent application WO 97/33916) is an IgG1 isotype, obtained from immunisation of Balb/c with SW1116 cells (colorectal adenocarcinoma), recognised an antigen expressed preferentially in the surface and cytoplasm of the malignant and normal colorectal cells. This antibody does not

recognise neither CEA, Lewis a, Lewis b, asialylated Lewis, membranes of normal mononuclear cells antigens nor red globules (Vázquez A. M. et al, Hybridoma 11, pag. 245-256, 1992).

Western blotting studies using SW1116 membranes extract showed that this antibody recognized a glycoprotein complex which was denominated ior C2, with two molecular weight forms (145 and 190 Kda) (Vázquez A. M. et al, Year Immunol. Basel, Karger, vol. 7, pag. 137-145, 1993).

Also it is known from the state of the art that using genetic engineering techniques, recombinant fragments can be constructed from monoclonal antibodies. There are many reports validating the use of different antibody fragments in the "in vivo" diagnosis and the therapeutic of the diseases.

Ira Pastan et al. (EP 0796334 A1) describes the construction of single chain Fv fragments, using variables regions of antibodies that specifically recognised carbohydrates related with Lewis Y antigen. Using these fragments, he developed a method to detect cells bearing this antigen. Also, he gives evidences of the inhibitor effect of these fragments on cells bearing the antigen.

## **DISCLOSURE OF THE INVENTION**

This invention is related to recombinant antibodies obtained using genetic engineering technology, specifically with a chimeric antibody, a humanised antibody and a single chain Fv fragment obtained from murine antibody IOR C5 antibody, produced by the hybridoma of the same name deposited in correspondence with the

Budapest Treaty under accession number ECCC 97061101 with European Collection of Cell Cultures, on June 11, 1997. This antibody recognizes epitopes expressed in ior C2 antigen, which is a glycoprotein complex that it is expressed in normal and malignant colorectal cells.

### **BRIEF DESCRIPTION OF THE FIGURES**

Figure 1: Shows the genetic construction of the plasmid pPACIB.9plus, which is a modified plasmid to express fusion proteins in the cytoplasm of E.coli. This plasmid contains regulatory sequences to get the following functions: Promoter sequence (tryptophan), 27aa fragment derived from IL-2h for getting efficient expression of the protein and, a domain of 6 histidines codified in mature protein's C-terminal to be used during the purification of this protein.

### **DETAILED DESCRIPTION OF THE INVENTION**

#### **cDNA Synthesis and Gene Amplification of the variable region of murine C5.**

Cytoplasmic RNA was extracted from about 106 hybridoma cells of the monoclonal antibody C5 (Vázquez A.M. et al. Year Immunol, Basel, Karger, vol 7, pag. 137-145, 1993). The method used to extract RNA was described by Faloro et al (Faloro,J.,Treisman,R.,and Kemen,R. (1989). Methods in Enzymology 65:718-749).

The cDNA synthesis reaction consisted of 5 ug RNA, obtained with 25 pmoles of the designed primers to hybridise in the beginning of the constant region of murine IgG1, and in the murine constant kappa region for the light chain, 2.5 mM each of deoxinucleotide (dNTPs), 50 mM Tris-Hcl pH 7.5, 75 mM KCl, 10 mM DTT, 8 mM MgCl2 and 15 u of ribonuclease inhibitor (RNA guard, Pharmacia) in a total volume

of 50  $\mu$ l. Samples were heated at 70°C, for 10 min and slowly cooled to 37°C over a period of 30 min. Then, 100 units reverse transcriptase were added and the incubation at 42°C continued for 1 hour.

The variable regions of light chain (VK) and heavy chain (VH) were amplified using Polymerase Chain Reaction (PCR). Briefly, 5  $\mu$ l cDNA of VH or VK were mixed with 25 pmoles of specific primers, 2.5 mM each of dNTP, 5  $\mu$ l buffer 10X for the enzyme DNA polymerase and 1 unit of this enzyme. Samples were subjected to 25 thermal cycles at 94°C, 30sec; 50°C, 30sec; 72°C, 1 min; and a last incubation for 5 min at 72 °C.

#### **Cloning and Sequencing of Amplified cDNA.**

The purified VH and VK cDNA were cloned into TA vector (TA Cloning kit. Promega, USA). Clones were sequenced by the dideoxy method using T7 DNA Pol (Pharmacia, Sweden).

#### **Construction of chimeric genes.**

The light and heavy chains variable regions were obtained by enzyme restrictions from TA vectors and cloned into expression vectors (Coloma M.J. et al., Journal of Immunological Methods, 152, 89-104, 1992).

The VH genes were cut from TA vector by EcoRV and NheI digestion, and cloned in PAH 4604 expression vector, an human constant IgG1 is included and histidinol resistance gene.

The resultant construction is C5VH-PAH4604. The VK genes were cut from TA EcoRV and Sall digestion and cloned in PAG4622. This vector contains resistance to the gpt and used kappa human constant region. The resultant construction is C5VK-PAG4622.

### **Chimeric antibody expression.**

NSO cells were electroporated with 10 µg of C5VH-PAH4604 and 10 ug of C5VK-PAG4622 and linearized by digestion with PvuI. The DNAs were mixed together, ethanol precipitated and dissolved in 25 µl water. Approximately 107 NSO cells were grown to semiconfluency, harvested by centrifugation and resuspended in 0.5 ml DMEN together with the digested DNA in an electroporation cuvette. After 5 minutes on ice, the cells were given a pulse of 170 volts and 960 µF) and left in ice for a further 30 minutes. The cells were then put into 20 ml DMEN plus 10% foetal calf serum and allowed recovering for 48 hours. At this time the cells were distributed into a 96 -well plate and selective medium applied (DMEN, 10% foetal calf serum, 0,8 µg/ml mycophenolic acid, 250 µg/ml xanthine). Transfected clones were visible with the naked eyes 10 days later.

The presence of the human antibody in the medium of wells containing transfected clones was measured by ELISA. Microtiter plate wells were coated with goat anti-human (gamma chain specific, After washing with PBST (phosphate buffered saline containing 0.02% Tween 20, pH 7.5), 100 µl of culture medium from the wells containing transfectants was added to each microtiter well for 1 hour at 37°C. The wells were washed with PBST and the conjugated goat anti- human Kappa, light

chain specific were added and incubated at room temperature for one hour. The wells were then washed with PBST and substrate buffer containing diethanolamine added. After 30 minutes the absorbency at 405 nm was measured.

### **Construction of humanised IOR C5h by T epitopes humanisation.**

#### **Prediction of T epitopes.**

The variable region sequences of IOR C5 were analysed using AMPHI program, which predicts segments of the sequences 7 or 11 amino acids in length with an amphipathic helix, which are related with T immunogenicity. Also it was used SOHHA program which predicts hydrophobic helix (Elliot et al. J. Immunol. 138: 2949-2952, (1987). These algorithms predict fragments related with T epitopes presentation in the light and heavy variable regions of the IOR C5.

#### **Analysis of homology of variable regions.**

The variable domains of IOR C5 are compared with those corresponding human variable domains, to identify the most homological human sequence with murine molecule. The human sequence databases used were reported in Gene Bank and EMBL, both of them available in Internet. The comparison was made by an automated-computerised method, PC-DOS HIBIO PROSIS 06-00, Hitachi.

#### **Analysis for immunogenicity reduction.**

The essence of this method lies in reducing the immunogenicity by humanisation of the possible T cell epitopes, with only few mutations in the FRs, specifically in the amphipathic helix, excluded the positions involved with the tridimensional structure of the binding site.

In this method it is compared VH and VK regions of the murine immunoglobuline, with the most homological human immunoglobuline sequence and it could be possible to identify the different residues between murine and human sequences, only inside the amphipatic regions, within the FRs zone (Kabat E.(1991) Sequences of proteins of immunological interest, Fifth Edition, National Institute of Health), only these murine residues will be mutated by those of the human sequence at the same position.

Those residues in the mouse framework responsible for the canonical structures or those involved in the Vernier zone can not be mutate, because they could have a significant effect on the tertiary structure and to affect the binding site. Additional information about the substitutions in the tertiary structure, could be obtain, doing a tridimensional molecular model of the variable regions.

#### **Cloning and Expression of humanised IOR C5 antibody into NSO cells.**

After doing PCR overlapping to get mutations and humanised VH and VK, the obtained genetic construction corresponding to IOR C5 by humanisation of T cell epitopes, were cloned into expression vectors in a similar way as used for the expression of the chimeric antibody, yielding the following plasmids: C5Vkhu-PAG4622 and C5Vhhu-PAH4604. The transfection of these genes into NSO cells was done in exactly the same conditions that we previously described for the chimeric antibody.

## **Obtainment of single chain Fv fragment. Construction and expression of the scFv.**

The strategy includes a first amplification using PCR, which modify VH and VL sequences, including the endonucleases restriction sites to clone in the expression vectors. The amplification used designed oligonucleotides on the exact sequence.

After amplifying, the variable regions are purified and digested with the corresponding restriction enzymes. The DNA fragments are purified and ligated to the expression vectors. Later, these genetic constructions are expressed in *E. coli*, following conventional methods.

In the extraction process of the protein from the producer cells, a rupture process by ultrasound is doing, and it is possible to separate the soluble and insoluble fractions combining SDS polyacrylamide electrophoresis gels, nitro-cellulose transfer and western blot.

Partial purification of the protein is carried out by a process which includes: (1) separation of the soluble and insoluble material by ultrasound and centrifugation, (2) Wash in low molarities of urea and solubilization in high concentrations of urea. From solubilized material, to purify the protein by affinity chromatography to metals ions. Later, the protein is renaturalised against buffer.

## **Examples**

### **Example 1. Obtainment of the Chimeric monoclonal antibody.**



The VH and VK cDNAs were obtained from RNA extracted from the hybridoma producing the monoclonal antibody IOR C5 using reverse transcriptase enzyme. The specific primers used were:

For VH:

5'-aggtctagaa ctctccacac acaggagagc cagtggatag ac-3' [SEQ. ID. NO. 15]

~~5'-AGGTCTAGAA(CT)CTCCACACACAGG(AG)(AG)CCAGTGGATAGAC-3'~~

For VK:

5'-gcgtctagaa ctggatggtg ggaagatgg-3' [SEQ. ID. NO. 16]

~~5'-GCGTCTAGAACTGGATGGTGGGAAGATGG-3'~~

The ADNc of the chains VH and VK were amplified using polymerase chain reaction (PCR) with Taq polymerase enzyme, and using specific primers ECORV/NHEI restriction site for VH and ECORV/SAL I for VK. The specific primers used were:

For VH:

Oligonucleotide 1:

5'-ggggatatcc accatggctg tcttggggct gctcttct-3' [SEQ. ID. NO. 17]

~~5'-GGGGATATCCACCATGGCTGTCTTGGGGCTGCTCTTCT-3'~~

Oligonucleotide 2:

5'-tggttcgaca tgatgggggc ttttgctga gctgaggaga c-3' [SEQ. ID. NO. 18]

~~5'-TGGGTCGAC(AT)GATGGGG(GC)TGTGTGCTAGCTGAGGAGAC-3'~~

For VK:

Oligonucleotide 1:

5'-ggggatatcc accatgaggg tcccatgac tcagcttct-3' [SEQ. ID. NO.

19]5'-GGGGATATCCACCATGAGG(GT)CCCC(AT)(GA)CTCAG(GT)T(GT)3'

Oligonucleotide 2:

5'-agcgtcgact tacgttttga ttccagact tgtgtccc-3' [SEQ. ID. NO.

20]5'-AGCGTCGACTTACGTTT(TG)ATTTCCA(GA)CTT(GT)GTCCC3'

The PCR products were cloned in TA vector (TA cloning kit, Invitrogen). Twelve independent clones were sequenced by dideoxy method using T7 DNA Pol (Pharmacia). The VH and VK sequences have high relation with the sub-group 2 of Kabat.

Then, VH chain was digested ECORV/NHEI and VK, ECORV/SALI, and cloned in PAH4604 and PAG4622 for VH and VK respectively. These vectors were donated by Sherie Morrison (UCLA, California, USA), and they are used for the immunoglobulines expression in mammalian cells. The PAH 4604 vector has included human constant region IgG1 and the PAG 4622 has human Ck (Novel vectors for the expression of antibody molecules using variable regions generated by polymerase chain reaction., M. Josefina Coloma et al, Journal of Immunological Methods, 152 (1992), 89-104) The resultant constructions after cloning IOR C5 regions were VHC5-PAH4604 and VKC5-PAG4622.

NSO cells were electroporated with 10 ug of the chimeric vector C5VH-PAH4604 and 10 ug of C5VK-PAG4622 and linearized by digestion with PvuI. The DNAs were mixed together, ethanol precipitated and dissolved in 25 ul water. Approximately 107

NSO cells were grown to semi-confluence, harvested by centrifugation and resuspended in 0.5 ml DMEN together with the digested DNA in an electroporation cuvette. After 5 minutes on ice, the cells were given a pulse of 170 volts and 960 uF and left in ice for a further 30 minutes. The cells were then put into 20 ml DMEN plus 10% foetal calf serum and allowed to recover for 48 hours. At this time the cells were distributed into a 96 -well plates and selective medium applied (DMEN, 10% foetal calf serum, 10mM histidinol). Transfected clones were visible with the naked eyes 10 days later.

The presence of chimeric antibody in the medium of wells containing transfected clones was measured by ELISA. Microtiter plate wells were coated with goat anti-human (gamma chain specific, Sara lab). After washing with PBST (phosphate buffered saline containing 0.02% Tween 20, pH 7.5), 20 ul of culture medium from the wells containing transfectants were added to each microtiter well for 1 hour at 37°C. The wells were washed with PBST and alkaline phosphatase conjugated goat anti- human Kappa, light chain specific were added and incubated at room temperature for one hour. The wells were then washed with PBST and substrate buffer containing dietanolamine added. After 30 minutes the absorbance at 405 nm was measured.

#### **Example 2. Obtainment of different versions of humanised antibody.**

The VH and VK IOR C5 sequences were compared with a human sequences database, obtaining the most human homological sequence with the IOR C5.

Then the amphipatic regions or possible T cell epitopes, were determined in VH and VK regions.

For VH, mutations were introduced in positions 10 and 17, and the amino acids ASP and SER by GLY and THR respectively, were substituted. These mutations were done by PCR overlapping, using primers 1 and 2, 3 and 4 in a first PCR and the results of these PCR were overlapped in a second PCR, using 2 and 4 primers, whose sequences are the following: (Kamman, M., Laufs, J., Schell, J., Gronemborg,

B. Rapid insertional mutagenesis of DNA by polymerase chain reaction (PCR).

Nucleic Acids Research 17:5404,1989).

Primers for the mutations 10 and 17 of the heavy chain.

Primer 1:

5'-gagtcaggac ctggcctggt gaaaccttct cagacacttt cactcacc-3' [SEQ. ID. NO. 21]

~~5'-GAGTCAGGACCTGGCCTGGTGAACCTTCTCAGACACTTTCACTCACC-3'~~

Primer 2:

5'-tgggtcgaca tgatgggggc tgttgctga gctgaagaga c-3' [SEQ. ID. NO. 22]

~~5'-TGGGTTCGAC(AT)GATGGGG(GC)TGTTGTGCTAGCTGAAGAGAC-3'~~

Primer 3:

5'-ggtgagtga agtgtctgag aaggtttcac caggccaggt cctgactc-3' [SEQ. ID. NO. 23]

~~5'-GGTGAGTGAAAGTGTCTGAGAAGGTTTCACCAGGCCAGGTCCTGACTC-3'~~

Primer 4:

5'-ggggatatcc accatggctg tctggggct gctcttct-3' [SEQ. ID. NO. 24]

~~5'-GGGGATATCCACCATGGCTGTCTTGGGGCTGCTCTTCT-3'~~

After the former mutations were verified by sequencing, new mutations were introduced to this mutated DNA, the new mutations introduced in positions 43 and 44 were LYS and GLY, substituting ASN and LYS respectively. The overlapping procedure was done as the previous overlapping. The mutations were verified by sequencing, this new construction was called C5VHhu.

The primers described for these mutations were:

Primers for the mutations 43 and 44 in the heavy chain.

Primer 1:

5'-cagtttcag gaaaaggact ggaatggatg-3' [SEQ. ID. NO. 25]

~~5'-CAGTTTCCAGGAAAAGGACTGGAATGGATG-3'~~

Primer 2:

5'-tgggtcgaca tgatgggggc tgttgctga gctgaagaga c-3' [SEQ. ID. NO. 26]

~~5'-TGGGTCGAC(AT)GATGGGG(GC)TGTTGTGCTAGCTGAAGAGAC-3'~~

Primer 3:

5'-catccattcc agtcctttc ctggaaactg-3' [SEQ. ID. NO. 27]

~~5'-CATCCATTCCAGTCCTTTTCCTGGAAACTG-3'~~

Primer 4:

5'-ggggatatcc accatggctg tctggggct gctcttct-3' [SEQ. ID. NO. 28]

~~5'-GGGGATATCCACCATGGCTGTCTTGGGGCTGCTCTTCT-3'~~

For VK the mutations were done in positions 15, 45 y 63 substituting ILE, LYS and THR, by LEU, ARG y SER, respectively.

The mutations were introduced by overlapping PCR as describe previously. The sequences of the used primers are shown. The new genetic construction was named C5Vkhu.

Primers for the mutation 15 of the light chain.

Primer 1:

5'-ttgtcggtta cccttgaca accagcc-3' [SEQ. ID. NO. 29]

~~5'-TTGTCGGTTACCCCTTGGACAACCAGCC-3'~~

Primer 2:

5'-agcgtcgact tacgtttga ttccagact tgtgtccc-3' [SEQ. ID. NO. 30]

~~5'-AGCGTCGACTTACGTTT(TG)ATTTCCA(GA)CTT(GT)GTCCC-3'~~

Primer 3:

5'-ggctggtgt ccaagggtaa ccgacaa-3' [SEQ. ID. NO. 31]

~~5'-GGCTGGTTGTCCAAGGGTAACCGACAA-3'~~

Primer 4:

5'-ggggatatcc accatgagg tcccatgac tcagttctc ttggt-3' [SEQ. ID. NO. 32]

~~5'-GGGGATATCCACCATGAGG(GT)CCCC(AT)(GA)CTCAG(CT)T(CT)CT(TG)GT~~

Primers for the mutation 45 of the light chain.

Primer 1:

5'-ggccagtctc caaggcgct aatctat-3' [SEQ. ID. NO. 33]

~~5'-GGCCAGTCTCCAAGGCGCCTAATCTAT-3'~~

Primer 2:

5'-agcgtcgact tacgtttga ttccagact tgtgtccc-3' [SEQ. ID. NO. 34]

~~5'-AGCGTCGACTTACGTTT(TG)ATTTCCA(GA)CTT(GT)GTCCC-3'~~

Primer 3:

5'-atagattagg cgccttgag actggcc-3' [SEQ. ID. NO. 35]

~~5'- ATAGATTAGGCGCCTTGGAGACTGGCC -3'~~

Primer 4:

5'-ggggatatcc accatgaggg tcccatgac tcagcttctc ttggt-3' [SEQ. ID. NO. 36]

~~5'- GGGGATATCCACCATGAGG(GT)CCCC(AT)(GA)CTCAG(CT)T(CT)CT(TG)GT~~

Primers for the mutation 63 of the light chain.

Primer 1:

5'-cctgacagat tcagtggcag tggatca-3' [SEQ. ID. NO. 37]

~~5'- CCTGACAGATTCAGTGGCAGTGGATCA -3'~~

Primer 2:

5'-agcgtcgact tacgtttga ttccagact tgtgtccc-3' [SEQ. ID. NO. 38]

~~5'- AGCGTCGACTTACGTTT(TG)ATTTCCA(GA)CTT(GT)GTCCC -3'~~

Primer 3:

5'-tgatccactg ccactgaatc tgtcagg-3' [SEQ. ID. NO. 39]

~~5'- TGATCCACTGCCACTGAATCTGTCAGG -3'~~

Primer 4:

5'-ggggatatcc accatgaggg tcccatgac tcagcttctc ttggt-3' [SEQ. ID. NO. 40]

~~5'- GGGGATATCCACCATGAGG(GT)CCCC(AT)(GA)CTCAG(CT)T(CT)CT(TG)GT~~

All the mutations were verified by sequence.

The humanised VK and VH were cloned into the vectors PAG4622 and PAH4604, the followings constructions were obtained, C5Vkhu-PAG4622 and C5VHhu-PAH4604.

The NSO cells were electroporated with 10 µg of the humanised C5VHhu-PAH4604 and 10 µg of the C5VKhu-PAG4622. These vectors were linearized with PVUI digestion.

The electroporation and detection of the clones expressing humanised antibody IOR C5h were identical to the previous described for the chimeric antibody.

### **Example 3. Construction of the single chain Fv fragment:**

Construction of the scFv fragment (VH-linker-VL), from variable domains (VH y VL) of IORC5 mAb. Cloning into expression vector to express in E.Coli.

Procedure (a). Construction of the scFv.-

The strategy has a first round of amplification by PCR, modifying sequenced VH and VL regions, including restriction endonucleases sites to cloning into the expression vectors pPACIB.7plus and pPACIB.9plus. In the amplification, the oligonucleotides designed under the exact sequence are used.

Heavy Chain:

4066: EcoRV-FR1-VH

5'-gggatatctg aggtgcagct tcaggagtca gga-3' [SEQ. ID. NO. 41]

5'-GGGATATCTGAGGTGCAGCTTCAGGAGTCAGGA-3'



4255: EcoRV-FR4-VH

5'-caggatatcg cagagacagt gaccagagtc cc-3' [SEQ. ID. NO. 42]

5'..CAGGATATCGCAGAGACAGTGACCAGAGTCCC..3'

Light Chain:

2938: Sal I-FR1-VL

5'-cgtcgacgat atccagatga caccagaact acc-3' [SEQ. ID. NO. 43]

5'.CGTCGACGATATCCAGATGAC(AC)CA(GA)ACT(AC)C..3'

2935: Apa I- FR4-VL

5'-atggggccctt ttcattgttc cagcttggt-3' [SEQ. ID. NO. 44]

5'.ATGGGGCCCTTT(TC)A(TG)(TC)TCCAGCTTGGT..3'

After amplifying the regions, were purified and digested VH (EcoRV) and VL (SalI-ApaI). The DNA fragments were purified and ligated with pPACIB.9plus and pPACIB.7plus, vectors, previously digested with restriction enzymes.

The plasmid pPACIB.7plus is modified to export to periplasm heterologous proteins whose genes are expressed in E.coli. This plasmid contains regulatory sequences to get the following functions: Promoter sequence (tryptophan), sequence for signal peptide (OMPA), sequence for linker peptide (Chaudhary et al., 1990) and a domain composed by 6 histidines codified in mature protein's C-terminal to help in the purification of this protein (Gavilondo, J.V. et al. Proceedings of the IV Annual Conference on Antibody Engineering. IBC Conferences Inc. Coronado, CA. December 8-10, 1993).

The plasmid pPACIB.9plus (Figure 1) is modified to express in the cytoplasm heterologous proteins whose genes are expressed in E.coli. This plasmid contains regulatory sequences to get the following functions: Promoter sequence (tryptophan), 27aa fragment derived from IL-2h for getting efficient expression of the protein, and a domain of 6 histidines codified in mature protein's C-terminal to help in the posterior purification of this protein (Gavilondo, J.V. et al. Proceedings of the IV Annual Conference on Antibody Engineering. IBC Conferences Inc. Coronado, CA. December 8-10, 1993).

The PCR reaction's product was used to transform the competent E.coli cells (strain MC1061), which were plated under solid selective medium and grown at 37°C. To select recombinant vectors, a bacterial colonies were inoculated in liquid medium and extracted plasmid DNA from this culture (Molecular Cloning, A Laboratory Manual, second edition, 1989, Sambrook, Fritsch and Maniatis). The plasmid DNA was digested by EcoRV, SalI/ApaI, XhoI/ApaI according cloning step, after applying under agarose gel and visualised with UV light, the recombinant clones were select between the clones with digestion pattern of two bands, one of them corresponding to pPACIB.7 and 9plus (approx. 2.9kb), and the second to the expected domain (approx. 320pb VH or VL y 720pb for the scFv). For VH domain the insertion orientation was checked by DNA sequencing.

Procedure (b). Expression of scFv in E.coli, obtained from variable domain genes of IOR C5 Mab.

Four strains of E. coli were transformed (TG1, coliB, W3110 y MM294), to study the cloned gene expression, using two recombinant plasmids selected in (a). Basically

the recombinant bacteria were grown in liquid medium (LB) with ampicillin, overnight at 37°C. From these cultures, were inoculated fresh cultures containing ampicillin, and incubated by 3 hrs at 37°C. Then, the expression of the protein was induced, adding to the culture beta-indolacrylic acid (inductor of the tryptophan promoter). The analysis of the samples in SDS polyacrylamide gels at 12%, indicated that a protein of approximately of 28kDa is expressed under these conditions, in the periplasmatic fraction for the construction of pPACIB.7plus and a 30 kDa band for the recombinant clone in pPACIB.9plus, which is expressed in TG1 in between 6-11% of the total bacterial protein. It demonstrated through a Western blot (Molecular Cloning, A Laboratory Manual, second edition de 1989, by Sambrook, Fritsch and Maniatis) with an antisera obtained in rabbit against Fab fragment of IOR C5 Mab, and immuno-purified, that this protein corresponds to scFv of IOR C5.

**Example 4. Obtention of the scFv from bacterial cultures, renaturalisation and recognition assays to antigen.**

Procedure (a). Extraction and renaturalisation of the scFv of IOR C5 from recombinant clone in pPACIB.9plus.-

In the extraction process of the protein from the producer cells using rupture ultrasound process, that allowed to separate soluble and insoluble fractions, combining with SDS-polyacrilamide electrophoresis gels, transferred to nitro-cellulose and Western blot, evidenced that the protein remains in the insoluble bacterial fraction.

Under these circumstances the protein was partially purified in a process including the followings steps:

- (1) separation of the soluble and insoluble material by ultrasound and centrifugation,
- (2) wash in low molarities of urea (2 M) and
- (3) solubilization to high molarities of Urea (6 M).

From the solubilized material, the protein is purified in affinity chromatography to metallic ions and renaturalised against buffer solution.

Procedure (b). Binding assay to tumour cells of the scFv-IORC5 fragment.

Cell lines:

The cells were obtained from Centro de Inmunología Molecular. SW948 adenocarcinome cell line was grown in L-15 medium supplemented with 10% bovine foetal serum at 37°C in 6 % CO<sub>2</sub>. Raji cell line (Burkitt human limphome) and Hut 78 (T human cell line) were used as negative controls.

These cell lines were grown in RPMI 1629 supplemented with 10% bovine foetal serum at 37°C.

The cell suspensions were fixed to 10<sup>6</sup> cell/ml in PBS containing 1% albumin of bovine serum. 10 ul of cell suspension was added to each well. The slides were dried in the dusty free air during 3 hours and fixed in acetone-methanol (1:1) solution, 5 minutes, and hydrated in TBS by 10 minutes. Finally, the cells were processed, using immunocytochemistry assay.

The activity of scFv IORC5 fragment was determined using immunocytochemistry assay, trough immunoperoxidase technique. The cells were incubated during 2 hours at 37°C with single chain Fv IOR C5, followed by incubation with anti Fab

serum and with an anti-mouse peroxidase conjugated (HRPO), each one for 30 minutes at room temperature. The localisation site of the peroxidase were visualised with solution which contains 5 mg of 3-3 diaminobencidine, 5 ml of TBS and 5 µl of H<sub>2</sub>O<sub>2</sub>, 30 %. Between incubations, the slides were washed with cold TBS.

After introducing in water, the slides were contrasted with Hematoxilline of Mayer and Canadian Balsam was added. Each experiment included positive and negative controls.

The immunocytochemistry studies revealed that this fragment is only positive to SW948 cell line, that showed a moderate labelled comparing with the complete Mab, demonstrated a specific recognition of the scFv IORc5 to this cell line. The label was associated to the membrane and cytoplasm compartment in the malignant colon cells.

#### **Brief description of the Figures.**

——— Figure 1: ~~Shows the genetic construction of the plasmid pPACIB.9plus, which is a modified plasmid to express fusion proteins in the cytoplasm of E.coli. This plasmid contains regulatory sequences to get the following functions: Promoter sequence (tryptophan), 27aa fragment derived from IL-2h for getting efficient expression of the protein and, a domain of 6 histidines codified in mature protein's C-terminal to be used during the purification of this protein.~~

## ABSTRACT

Novel ~~The invention relates to the obtention of novel~~ recombinant antibodies from murine antibody IOR C5 produced by the hybridoma deposited with the ECCC 97061101 ~~according to the Budapest Treaty.~~ Said recombinant antibodies were obtained using recombinant DNA technology and are characterized in that they recognize antigen ior C2. The recombinant antibodies are specifically chimeric antibody, humanized antibody, and single chain Fv fragment. The chimeric antibody contains the variable domains of the murine immunoglobuline and the constant regions of the human immunoglobuline. The humanized antibody contains the constant regions of human immunoglobuline and has been specifically modified in the murine frameworks regions (FRs) and within the latter, in those areas that may result in an antigenic site for cells T. The Fv fragment contains the variable domains of murine immunoglobuline. The invention also relates to the utilization of recombinant antibodies derived from murine antibody ior C5 in the diagnosis and therapy of colorectal tumors, the metastasis thereof and recurrences.